Table 2. Use of SGLT2 Inhibitors by Time.

	Empagliflozin	Placebo
All participants	N=3304	N=3305
Active trial period
12 months	2920/3164 (92%)	21/3159 (1%)
24 months	1661/1884 (88%)	41/1875 (2%)
36 months	270/326 (83%)	12/323 (4%)
Participants entering PTFU	N=2472	N=2419
Active trial period
12 months	2264/2423 (93%)	13/2363 (1%)
24 months	1319/1483 (89%)	30/1417 (2%)
36 months	254/297 (86%)	10/289 (3%)
Post-trial period
12 months	885/2186 (40%)	804/2147 (37%)
24 months	1078/2376 (45%)	972/2312 (42%)

Active trial periods defined using 12, 24, and 36 months follow-up visit windows. Use in the active trial defined as a participant reporting taking ≥80% of allocated study drug or open-label SGLT2 inhibitor (denominators are those known to be alive in each period). Post-trial periods defined using information nearest to 12 and 24 months since completion of active trial follow-up. Post-trial open-label SGLT2 inhibitor use was ascertained from review of participant’s medical records, or where necessary, direct contact with participants (denominators are those who joined post-trial follow-up, had a follow-up in the period and were known to be alive in the relevant period). Use of open-label SGLT2 inhibitor in the empagliflozin group versus placebo group in the post-trial period after excluding participants on kidney replacement therapy in the relevant periods was 880/2032 (43%) vs 797/1960 (41%) at 12 months and 1069/2129 (50%) vs 961/2015 (48%) at 24 months.